A series of progressively more attenuated cold-passaged (cp), temperature-sensitive (ts) intranasally administered RSV vaccines are being evaluated in placebo-controlled, randomized, double-blinded trials in young children. In all preclinical testing, including administration to chimpanzees, the current vaccine candidate, cpts248/404, was more highly attenuated than the strains recently described by Karron et al (JID 176:1428-36, 1997). The vaccine failed to infect 15 seropositive children, 15-59 months of age. The vaccine was safe, infectious, immunogenic and genetically stable in 45 seronegative 6-24 month old children at doses of 104 pfu(16) and 105 pfu(29). Results were similar in 16 children 3-5 months of age at 105. We next administered 2 doses of vaccine 8 weeks apart at 104 (10 children) or 105 (25 children) in the target age group of 4-12 week old infants. The first dose of vaccine was infectious at both dosage levels with all 7 vaccinees shedding virus following a 104 dose and 76% (13/17 vaccinees) shedding at a 105 dose. The amount of virus detected in nasopharyngeal washes was equal to that in older children (peak mean titer ≥ 4 log10 pfu/ml for both dosages). Two isolates showed a drift in their ts shut-off temperature from 36 to 37°C, indicating a very high level of genetic stability. At either dosage, vaccine caused mild to moderate nasal congestion without fever or any signs of lower respiratory tract involvement between 7-10 days after vaccine administration. With the second dose of vaccine virus there were no clinical symptoms and shedding was markedly curtailed (0/7 at the 104 dose) and(4/15 at 105) indicating protection conferred by the first dose of vaccine. Preliminary results suggest that protection occurs in the absence of detectable serum neutralizing antibody responses. Administration of cpts 248/404 live, attenuated RSV vaccine to 1-2 month old infants was accompanied by URI symptoms that will necessitate a slightly more attenuated vaccine. Nevertheless, for the first time a vaccine was administered to the target age group and induced protective immunity.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wright, P., Karron, R., Crowe, J. et al. Evaluation of a Live, Attenuated Respiratory Syncytial Virus (RSV)Vaccine Candidate, cpts 248/404, in Infancy • 931. Pediatr Res 43 (Suppl 4), 161 (1998). https://doi.org/10.1203/00006450-199804001-00952
Issue Date:
DOI: https://doi.org/10.1203/00006450-199804001-00952